JRoon, I still think there's a chance. In my view, it's not over yet until I see something posted on clinical trials.gov. The VA retrospective study was only for 9.4 months, 2144 patients in each arm (IPE vs Lovaza i'm assuming), and we see a 38% RRR in mace. MITIGATE would be 1500 vs a much bigger control group, and the mean followup should be closer to 12 months or longer.
Market Data 
Markets 
AI
